DQP 1105 is primarily used as a selective antagonist for the metabotropic glutamate receptor subtype 1 (mGluR1). It is widely utilized in neuroscience research to study the role of mGluR1 in synaptic transmission, neuronal excitability, and neurodegenerative conditions. Due to its high selectivity, it helps in dissecting signaling pathways involved in motor coordination, learning, and memory. It has also been employed in preclinical models to investigate potential therapeutic applications in diseases such as Parkinson’s, chronic pain, and certain types of cancer where mGluR1 signaling may be dysregulated. Its application is mainly restricted to in vitro and animal studies, serving as a valuable tool compound for target validation and mechanistic exploration.